The proposed scoring system in the current study identified ALT ≥ 16.2 U/L indicating a mildly increased risk of liver cancer and ALT ≥ 47 U/L indicating a markedly elevated risk of liver cancer. The gene discussed is GPT; the disease is liver cancer.